Eric Adler - Nov 2, 2023 Form 3 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role
Chief Scientific Officer
Signature
/s/ Jenny Robertson, Attorney-in-Fact
Stock symbol
LXEO
Transactions as of
Nov 2, 2023
Transactions value $
$0
Form type
3
Date filed
11/2/2023, 09:14 PM
Next filing
Feb 6, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LXEO Employee Stock Option (right to buy) Nov 2, 2023 Common Stock 39.3K $4.87 Direct F1
holding LXEO Employee Stock Option (right to buy) Nov 2, 2023 Common Stock 26.7K $4.87 Direct F2
holding LXEO Employee Stock Option (right to buy) Nov 2, 2023 Common Stock 181K $17.59 Direct F3
holding LXEO Employee Stock Option (right to buy) Nov 2, 2023 Common Stock 9.44K $11.02 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares underlying the option vested or shall vest in monthly installments commencing on August 16, 2021, subject to the Reporting Person's continuous service.
F2 Fully vested and exercisable.
F3 25% of the shares underlying the option vested on August 1, 2023, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F4 25% of the shares underlying the option shall vest on August 22, 2024, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney